Related Experiment Video
Updated: Jun 28, 2025
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities
Luca Potestio1, Nello Tommasino2, Giuseppe Lauletta2
1Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131, Naples, Italy. potestioluca@gmail.com.
Insights
Psoriasis patients face higher cardiovascular risks due to systemic inflammation and associated factors. This review examines biologic drugs for psoriasis in preventing heart complications.
Area of Science:
- Dermatology and Immunology
- Cardiology
- Systemic Inflammatory Diseases
Background:
- Psoriasis is recognized as a systemic disease with numerous comorbidities.
- Cardiovascular diseases are significant comorbidities in psoriasis patients, with increased risks of major adverse cardiovascular events.
- Risk factors like smoking, obesity, metabolic syndrome, hypertension, dyslipidemia, diabetes, and inactivity are linked to psoriasis, further elevating cardiovascular risk.
Purpose of the Study:
- To evaluate the effectiveness and safety of biologic drugs in managing psoriasis.
- To investigate the role of these biologics in preventing cardiovascular complications in psoriasis patients.
- To inform treatment decisions by considering cardiovascular risk in psoriasis management.
Main Methods:
- Systematic review of existing literature.
- Analysis of studies on biologic drugs targeting psoriasis pathogenesis.
- Assessment of data on cardiovascular outcomes in patients treated with these biologics.
Main Results:
- Biologic therapies targeting molecular pathways in psoriasis pathogenesis were reviewed.
- Evidence regarding their impact on preventing cardiovascular complications was analyzed.
- Safety and efficacy data relevant to cardiovascular health were considered.
Conclusions:
- Biologic drugs offer a potential avenue for managing psoriasis and its associated systemic effects.
- Further research is needed to fully elucidate the cardiovascular benefits and risks of specific biologic therapies in psoriasis patients.
- Integrating cardiovascular risk assessment into psoriasis treatment strategies is crucial.
Abstract:
Psoriasis is now considered a systemic disease, and several comorbidities have been described such as cardiovascular diseases, neurologic and psychiatric disorders, chronic inflammatory bowel disease, psoriatic arthritis, etc. Regarding cardiovascular comorbidities, major adverse cardiovascular events have been reported in psoriasis patients by multiple epidemiologic studies. Moreover, smoking, obesity, metabolic syndrome, hypertension, dyslipidemia, diabetes and reduced physical activity are associated with psoriasis, increasing cardiovascular risk. Consequently, several aspects should be considered when making the treatment decision. The aim of this review manuscript was to investigate the effectiveness and safety of biologic drugs acting on molecular mechanisms involved in the pathogenesis of psoriasis in preventing cardiovascular complications.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...